|
Re: Context on Sales Potential for an oral anti-viral & anti-inflammation combo
|
4
|
Resverlogix Corp.
|
Apr 14, 2021 05:38PM
|
|
Re: Breakthrough Therapy Question
|
4
|
Resverlogix Corp.
|
Jan 06, 2020 04:24PM
|
|
The Shorts
|
4
|
Resverlogix Corp.
|
Sep 07, 2018 02:46PM
|
|
Re: 300+ lots on the ask at $4.50 now....will it fall
|
4
|
Resverlogix Corp.
|
Apr 23, 2019 07:21PM
|
|
Re: Buyers need sellers....why I think delivery failures are important
|
4
|
Resverlogix Corp.
|
Nov 09, 2019 11:58AM
|
|
Re: Q3 Events updated
|
4
|
Resverlogix Corp.
|
Aug 10, 2017 11:47PM
|
|
Re: Array and Zenith
|
4
|
Zenith Epigenetics
|
Jun 22, 2019 02:17PM
|
|
Re: Just got word....
|
4
|
Resverlogix Corp.
|
May 31, 2019 02:42AM
|
|
Welcome to the RVX Hub on Agoracom
|
4
|
Resverlogix Corp.
|
Jun 25, 2019 02:19PM
|
|
Re: Article in National Post Feb 11
|
4
|
Resverlogix Corp.
|
Feb 12, 2022 01:17PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 04:17PM
|
|
Re: Milestone deal history?
|
4
|
Resverlogix Corp.
|
Jul 12, 2017 11:33AM
|
|
Re: Apabetalone......a Calculated Risk
|
4
|
Resverlogix Corp.
|
Apr 07, 2019 04:26PM
|
|
Re: List of illlnesses our drugs could possibly treat...
|
4
|
Resverlogix Corp.
|
Feb 06, 2019 11:49AM
|
|
Re: Preview Part II....
|
4
|
Resverlogix Corp.
|
Mar 30, 2017 10:25PM
|
|
Re: MD&A out
|
4
|
Resverlogix Corp.
|
Dec 15, 2018 02:45AM
|
|
Re: Number of shares to compute the price per share
|
4
|
Zenith Epigenetics
|
Oct 04, 2017 01:14AM
|
|
Re: Options
|
4
|
Resverlogix Corp.
|
Oct 23, 2019 01:03PM
|
|
Re: Late Breaker program?
|
4
|
Resverlogix Corp.
|
Mar 23, 2020 05:35AM
|
|
Re: Saudi
|
4
|
Resverlogix Corp.
|
Jan 17, 2021 02:36AM
|
